Skip to main content

Table 2 Clinical and microbiological outcome and mortality in patients receiving systemic or systemic + inhaled colistin therapy

From: Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?

  PE colistin PE and inh. colistin p
n (%) n (%)
Clinical outcome
 Clinical success 30 (37.5) 16 (37.2) 0.974
 Partial clinical
improvement
15 (18.8) 1 (2.3) 0.009
 Clinical failure 33 (41.3) 22 (51.2) 0.291
 Recurrence 2 (2.5) 4 (9.3) 0.094
Microbiological outcome
 Eradication 40 (50) 20 (46.5) 0.712
 Persistence 30 (37.5) 19 (44.2) 0.470
 Recurrence 4 (5) 4 (9.3) 0.356
 Colonization 6 (7.5) 0 (0) 0.062
 Mortality 38 (47.5) 23 (53.5) 0.526
Side effects
 Nephrotoxicity 43 (53.8) 21 (48.8) 0.603
 Neurotoxicty 0 0  
 Local side effects 0 0
  1. PE parenteral; Inh inhaled